Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asthma entities.

W J Calhoun1

  • 1Asthma Program, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.

Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
PubMed
Summary
This summary is machine-generated.

Asthma is a complex syndrome with varied underlying mechanisms. Identifying distinct asthma subtypes is crucial for personalized treatment and improving research accuracy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current prospective of aldose reductase inhibition in the therapy of allergic airway inflammation in asthma.

Current molecular medicine·2011
Same author

Can anti-IgE therapy prevent airway remodeling in allergic asthma?

Allergy·2011
Same author

Predicting worsening asthma control following the common cold.

The European respiratory journal·2008
Same author

Anti-leukotrienes for asthma.

Current opinion in pharmacology·2001
Same author

Increased nitric oxide production by airway cells of sensitized and challenged IL-10 knockout mice.

Journal of leukocyte biology·2001
Same author

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.

American journal of respiratory and critical care medicine·2001
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Pulmonology
  • Immunology
  • Genetics

Background:

  • Asthma is a chronic respiratory disease characterized by variable airflow limitation, airway hyperresponsiveness, and inflammation.
  • The underlying mechanisms of asthma development are diverse and can coexist within individuals.
  • Current diagnostic methods may not fully differentiate these mechanisms, leading to heterogeneity in asthma presentation and treatment response.

Purpose of the Study:

  • To emphasize the clinical and research value of distinguishing asthma subtypes.
  • To highlight how understanding mechanistic differences can guide personalized and cost-effective therapeutic strategies.
  • To address the significant intersubject variability in asthma research by defining more homogeneous patient subsets.

Main Methods:

Related Experiment Videos

  • Review of existing literature on asthma pathophysiology and classification.
  • Analysis of clinical observations regarding treatment efficacy across different patient groups.
  • Conceptual framework for stratifying asthma based on underlying mechanisms.

    • Main Results:

    • Asthma is not a single entity but a syndrome with multiple distinct underlying mechanisms.
    • Clear distinctions between mechanistic subtypes can yield significant therapeutic insights.
    • Coexisting mechanisms or limitations in current technology can obscure subtype identification in some patients.

    Conclusions:

    • Distinguishing asthma subtypes is essential for optimizing clinical management and improving therapeutic outcomes.
    • Recognizing mechanistic heterogeneity can reduce variability in asthma research, leading to more robust and definitive findings.
    • Further research into asthma phenotyping and endotyping is critical for advancing personalized medicine approaches.